Previous 10 | Next 10 |
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that it...
Celsion advances Phase II advanced ovarian cancer trial Celsion Corporation (CLSN) announced that it has randomized the first two patients in the Phase II portion of its OVATION 2 study. The company expects the enrollment to be completed by the third quarter of 2021. It is likely that th...
Aerie Pharmaceuticals (NASDAQ: AERI ) announces positive results from a 49-subject Phase 2 clinical trial evaluating two formulations of AR-1105 (dexamethasone intravitreal implant) in patients with macular edema associated with retinal vein occlusion. More news on: Aerie Pharmaceuti...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today reported positive...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and potentially other diseases of the eye, ...
Aerie Pharmaceuticals ( AERI ) is a stock I’ve owned for a while, and lately I wanted to revisit my prior analysis to see if it was worth buying more to average down my cost basis after a substantial share price decline from higher levels in 2018 and 2019. Although it’s a fairly ...
Aerie Pharmaceuticals, Inc. (AERI) Q1 2020 Earnings Conference Call May 6, 2020 5:00 P.M. ET Company Participants Ami Bavishi - Director of Investor Relations Vince Anido - Chairman and Chief Executive Officer Tom Mitro - President and Chief Operating Officer Rich Rubino - Chie...
Image source: The Motley Fool. Aerie Pharmaceuticals Inc (NASDAQ: AERI) Q1 2020 Earnings Call May 7, 2020 , 8:00 p.m. ET Operator Continue reading
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announc...
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye announced tod...
News, Short Squeeze, Breakout and More Instantly...
Aerie Pharmaceuticals Inc. Company Name:
AERI Stock Symbol:
NASDAQ Market:
Aerie Pharmaceuticals Inc. Website:
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Al...
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million, up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceut...
NEW YORK, NY / ACCESSWIRE / October 30, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Altra Industrial Motion Corp. (NA...